Literature DB >> 16204238

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

Catherine Rabu1, Agnès Quéméner, Yannick Jacques, Klara Echasserieau, Patricia Vusio, François Lang.   

Abstract

The interaction between 4-1BB ligand (CD137L), a member of the tumor necrosis factor superfamily, and its receptor 4-1BB provides a co-stimulatory signal for T lymphocyte proliferation and survival. However, the structure of 4-1BBL has not been thoroughly investigated, and none of the human recombinant 4-1BBL molecules available have been described as capable of co-stimulating T cells. The present work provides a model of the three-dimensional structure of the tumor necrosis factor homology domain of 4-1BBL and describes the production of a recombinant human soluble 4-1BBL whose originality lies in that it contains the whole extracellular tail preceding the tumor necrosis factor homology domain and an AviTag peptide (AviTag-4-1BBL) allowing enzymatic biotinylation and multimerization via streptavidin. We provide evidence that this chimeric protein exists as a homotrimer, whereas commercial FLAG-tagged 4-1BBL does not. This resulted in a much higher affinity for 4-1BB (1.2 nM) as compared with FLAG-4-1BBL (55.2 nM). We demonstrate that the single extracellular cysteine residue in the tail (Cys-51) could form a disulfide bond, both in our recombinant protein and in physiologically expressed 4-1BBL. The mutation of this cysteine residue exerted no effect on trimerization but increased the dissociation rate of AviTag-4-1BBL from 4-1BB. In its soluble form, AviTag-4-1BBL did not stimulate purified T cells but dramatically inhibited proliferation of peripheral blood mononuclear cells stimulated with anti-CD3 mAb. In contrast, a very significant co-stimulatory effect was observed on purified T cells once AviTag-4-1BBL was immobilized onto streptavidin beads. In addition, we show that the cross-linking of two trimeric AviTag-4-1BBL molecules was the minimum step required to elicit significant costimulatory activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204238     DOI: 10.1074/jbc.M506881200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

2.  Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

Authors:  Sina Fellermeier; Nadine Beha; Jan-Erik Meyer; Sarah Ring; Stefan Bader; Roland E Kontermann; Dafne Müller
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

3.  Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Authors:  Nicholas P Morris; Carmen Peters; Ryan Montler; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Andrew D Weinberg
Journal:  Mol Immunol       Date:  2007-03-19       Impact factor: 4.407

4.  T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model.

Authors:  Chunhui Jin; Xiaoqing Duan; Yingying Liu; Jianhong Zhu; Ke Zhang; Yuanting Zhang; Tingting Xia; Yajun Fei; Jianxin Ye
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

5.  4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Rich-Henry Schabowsky; Abhishek K Srivastava; Kutlu G Elpek; Shravan Madireddi; Hong Zhao; Zhenping Zhong; Robert W Miller; Kathryn J Macleod; Esma S Yolcu; Haval Shirwan
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 6.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

7.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 8.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

9.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

10.  Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

Authors:  Aruna Bitra; Tzanko Doukov; Jing Wang; Gaelle Picarda; Chris A Benedict; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.